Tymlos (Abaloparatide) in Children Under 12: Developmental Impact, Growth Plate Risk, and What Families Need to Know

The Short Answer: Abaloparatide Is Not for Children Under 12

Abaloparatide (Tymlos, Radius Health) has no approved indication in anyone under 18, and the FDA prescribing label explicitly contraindicates its use in pediatric patients with open epiphyses. This is not a precautionary footnote buried in fine print. It is a hard stop backed by animal carcinogenicity data and basic bone-physiology reasoning.

If you are a parent reading this because your daughter under 12 has a bone-fragility condition, or if you are a clinician considering whether abaloparatide could help a young patient, the answer the evidence currently supports is: this drug should not be used in that context. The sections below explain the science behind that conclusion and describe what management options do exist for pediatric bone disease in girls.

What Abaloparatide Is and How It Works in Bone

Abaloparatide is a synthetic analog of parathyroid hormone-related protein (PTHrP), specifically engineered to preferentially bind the RG conformation of the PTH1 receptor. This receptor-selectivity profile is designed to favor bone formation signaling over bone resorption, a property that distinguishes it mechanistically from teriparatide (PTH 1-34).

The Anabolic Bone Mechanism

When injected once daily, abaloparatide produces a transient pulse of PTH1R activation. Phase 3 trial data from the ACTIVE trial (N=2,463 postmenopausal women) showed an 86% reduction in new vertebral fractures versus placebo over 18 months. Total hip bone mineral density increased by 3.4% and lumbar spine BMD increased by 9.2% from baseline. These results are compelling in a population whose bone-forming cells (osteoblasts) are in a hormonally depleted, low-turnover state.

Why the Mechanism Is Specifically Problematic in Growing Bone

That same anabolic drive on the PTH1R is exactly why abaloparatide poses theoretical developmental risk in children. The PTH1R is not just a bone-density regulator in adults. In children, it governs chondrocyte differentiation in the growth plate. PTHrP signaling through this receptor controls the pace at which chondrocytes mature and whether the physis stays open and growing. Disrupting that tightly regulated process with a pharmacological PTHrP analog could, in principle, alter longitudinal bone growth, accelerate or delay physeal fusion, or change trabecular architecture during a window when skeletal geometry is being established for life.

No controlled human data in children under 12 test this hypothesis. The concern is extrapolated from receptor biology, animal studies, and analogy to what happens when PTH1R gain-of-function mutations occur naturally in children (Jansen metaphyseal chondrodysplasia, a rare condition causing severe skeletal abnormalities). That extrapolation is sufficient, in the absence of safety data, to make pediatric use unjustifiable.

The Osteosarcoma Black-Box Warning: What It Means for Young Patients

Every prescriber who has written for Tymlos has seen the bolded black-box warning. The FDA requires the warning because Fischer 344 rats given daily subcutaneous abaloparatide for 2 years developed osteosarcoma in a dose-dependent fashion. The incidence was higher at doses that produced systemic exposures exceeding those in humans, but the signal was present even at lower dose ranges.

Translating Rat Data to Human Risk

Rats have a higher baseline rate of spontaneous osteosarcoma than humans, and Fischer 344 rats are known to be particularly susceptible. The carcinogenicity study was a lifetime exposure model, whereas abaloparatide in clinical practice is capped at a cumulative lifetime limit of 2 years (combined with any prior teriparatide use). Post-marketing surveillance and the ACTIVExtend study, which followed patients for an additional 24 months on alendronate after completing abaloparatide, did not identify any osteosarcoma cases in the human trial population.

The human osteosarcoma signal remains unproven but also unrefuted, because no trial has been designed to detect it over the long follow-up that would be required. The FDA's position is that the risk cannot be excluded.

Why Children Face a Higher Theoretical Osteosarcoma Risk

Osteosarcoma is, in clinical practice, predominantly a disease of rapidly growing bone. Peak incidence in humans occurs during the adolescent growth spurt, when osteoblasts are most mitotically active. The American Cancer Society reports that about 800 new osteosarcomas are diagnosed annually in the U.S., with the highest rates in adolescents aged 10-19. If the anabolic stimulus of abaloparatide amplifies osteoblast proliferation, introducing that stimulus during a developmental window already characterized by peak osteoblast activity is a risk-multiplication scenario, not simply the same risk carried forward from adults.

This reasoning alone, even without direct human pediatric trial data, forms a strong scientific basis for the contraindication.

Growth Plate Physiology and Why Open Epiphyses Change the Risk Calculus

In children under 12, most long bones have open growth plates. The physis is a cartilaginous layer where chondrocyte columns proliferate, hypertrophy, and are replaced by bone in a process tightly regulated by PTHrP, Indian hedgehog (Ihh), fibroblast growth factors, and other signals.

PTHrP's Normal Role in Skeletal Development

PTHrP produced locally in the periarticular perichondrium slows the rate of chondrocyte hypertrophy and delays physeal ossification, keeping growth plates open and functional. Research published in the New England Journal of Medicine on PTH1R mutations demonstrated that both loss-of-function (Blomstrand chondrodysplasia) and gain-of-function (Jansen metaphyseal chondrodysplasia) PTH1R variants produce severe, life-altering skeletal phenotypes in children, underscoring how sensitive the developing skeleton is to perturbations in this pathway.

Administering a pharmacological PTHrP analog to a child with open growth plates would introduce a non-physiological, systemically delivered signal into a circuit that normally depends on local, paracrine PTHrP gradients. The consequences could include abnormal growth plate widening, altered metaphyseal remodeling, or disruption of the coordinated Ihh-PTHrP feedback loop that regulates chondrocyte column organization.

What "Open Epiphyses" Means in Practice for Girls

In girls specifically, the timing of physeal closure is hormonally driven and roughly follows:

• Long bone physes (femur, tibia): close approximately 14-17 years of age, earlier in girls than boys
• Vertebral ring apophyses: may not fully fuse until the early 20s
• Girls with conditions causing delayed puberty (Turner syndrome, hypothalamic amenorrhea, anorexia nervosa) may have open physes well beyond typical age ranges

Estrogen is the primary driver of physeal fusion in girls, and conditions of estrogen deficiency delay closure significantly. A girl under 12 has open physes throughout her skeleton. Any drug with PTH1R agonist activity introduced during this window has unpredictable effects that have simply not been studied.

What the Evidence Actually Shows: Trials, Animal Data, and the Knowledge Gap

To be precise about what is known versus extrapolated, here is a structured breakdown of the current evidence base:

What Has Been Directly Studied

• Postmenopausal women, 18-month treatment: The ACTIVE trial is the primary efficacy and safety database. Mean age 69 years. All participants were postmenopausal with confirmed osteoporosis or low bone mass plus risk factors. Vertebral fracture reduction was 86% versus placebo (RR 0.14, 95% CI 0.05-0.39).
• Rat carcinogenicity (lifetime exposure): Osteosarcoma at doses above clinical range. Dose-response relationship present.
• Juvenile rat studies (referenced in prescribing information): Abaloparatide administered to young rats produced periosteal bone formation changes and effects on growth plate morphology. These findings are cited in the label as grounds for the pediatric contraindication but are not published in full peer-reviewed form accessible on standard databases.

What Has Not Been Studied in Humans

• Any dose of abaloparatide in children under 18
• Pharmacokinetics of abaloparatide in prepubertal or pubertal girls
• Effect on growth velocity, final height, or skeletal geometry in developing humans
• Safety in girls with primary bone fragility disorders (osteogenesis imperfecta, idiopathic juvenile osteoporosis)

The evidence gap here is substantial. Women have historically been underrepresented in clinical trials generally, and pediatric girls with bone disease represent an almost completely unstudied subgroup for this drug class. That is not a caveat to mention in passing. It means that any use of abaloparatide in a girl under 12 would be genuinely experimental, without a safety or dosing framework.

Conditions in Young Girls That Raise Questions About Bone Health

Parents and pediatric clinicians sometimes encounter this question because a girl under 12 has a condition associated with fragile bones or low BMD. The relevant conditions include:

Osteogenesis Imperfecta (OI)

OI is caused by COL1A1/COL1A2 mutations affecting type I collagen. Girls with OI type I (mild) may have multiple fractures in childhood. Current standard of care for moderate-to-severe OI in children uses cyclical intravenous bisphosphonates, particularly pamidronate or zoledronic acid, based on controlled trial data showing reduced fracture rates and improved vertebral morphology. Abaloparatide has no evidence base in OI of any age, let alone in children.

Idiopathic Juvenile Osteoporosis (IJO)

IJO is a self-limited condition typically appearing before puberty and resolving spontaneously with the onset of puberty. Management is largely supportive, with physical activity optimization and calcium and vitamin D adequacy. No anabolic agent has an established role in IJO.

Secondary Osteoporosis in Chronic Disease

Girls with chronic conditions including inflammatory bowel disease, cystic fibrosis, leukemia treated with corticosteroids, or celiac disease may have significantly reduced bone mass. Bisphosphonates remain the most studied pharmacological intervention in these populations under specialist guidance.

Turner Syndrome

Girls with Turner syndrome (45,X) have skeletal abnormalities related to estrogen deficiency and SHOX gene haploinsufficiency. Estrogen replacement therapy started at the appropriate developmental stage is the cornerstone of bone protection in Turner syndrome. The American Society for Reproductive Medicine and endocrinology guidelines support early estrogen initiation in Turner syndrome to optimize peak bone mass. Abaloparatide has no studied role here.

Pregnancy, Lactation, and Contraception: Required Information

Even though abaloparatide is not used in children, any drug article on this platform requires full pregnancy and lactation information for the women who are prescribed this drug in its approved indication.

Pregnancy

Abaloparatide is contraindicated in pregnancy. Animal reproductive toxicology studies showed fetal toxicity at doses producing exposures below those achieved with the clinical 80 mcg dose. The drug is assigned no formal FDA pregnancy letter category under the current labeling system (post-2015 PLLR format), but the label states clearly: "Based on animal data, abaloparatide may cause fetal harm."

There are no adequate and well-controlled studies of abaloparatide in pregnant women. The drug should be stopped immediately if pregnancy is confirmed. Women of reproductive age prescribed abaloparatide for any reason must use effective contraception throughout treatment.

Lactation

No data exist on the presence of abaloparatide in human breast milk, its effect on milk production, or its effect on the breastfed infant. The FDA label recommends against use during breastfeeding, and clinicians should advise patients to pump and discard milk or use formula if abaloparatide treatment cannot be interrupted.

Contraception Requirement

Because abaloparatide is primarily used in postmenopausal women (the approved population), routine contraception counseling is not in most prescribers' workflow for this drug. However, if abaloparatide were ever considered off-label in a perimenopausal woman whose menopausal status was not confirmed by 12 months of amenorrhea, or in a younger woman with premature ovarian insufficiency who retains any residual ovarian function, reliable contraception is mandatory. Spontaneous conception in women using abaloparatide would constitute a significant fetal exposure risk.

Life-Stage Context: Who Abaloparatide Is For, and Who It Is Not

Understanding where abaloparatide sits across the female life cycle clarifies why pediatric use is so far outside its intended and studied scope.

Postmenopausal Women (Primary Approved Population)

The drug was designed for and studied in postmenopausal women with osteoporosis, a population in whom estrogen deficiency has driven net bone loss, osteoblast activity is relatively suppressed, and growth plates have been closed for decades. In this context, an anabolic stimulus that increases osteoblast activity and periosteal apposition addresses the underlying biology directly. The ACTIVE trial enrolled women aged 49-86, mean age 69, with T-scores of -2.5 or lower or prior fragility fracture.

Perimenopausal Women

No specific trial data support use in perimenopausal women. Perimenopausal bone loss occurs and can be substantial, but the indication threshold (T-score at osteoporosis range or prior fracture) must still be met, and ovarian function must be reliably assessed.

Reproductive-Age Women

No approved indication. No safety data. Contraindicated in pregnancy. This group should never receive abaloparatide except under extraordinary and carefully documented circumstances.

Adolescent Girls (12-17)

No approved indication. Open growth plates in many 12-17 year olds, especially early in this range, add developmental risk on top of the general pediatric contraindication. The 2-year lifetime cap further limits utility in a young patient who might theoretically need bone-building treatment across decades.

Girls Under 12

Absolutely contraindicated. Open physes throughout the skeleton. No pharmacokinetic data. No safety data. The osteosarcoma signal in the context of high baseline osteoblast activity during growth is a compounding concern. No clinical scenario currently justifies use in this group.

What Should Be Done Instead: Evidence-Based Alternatives for Bone Fragility in Girls Under 12

The absence of abaloparatide as an option does not leave clinicians without tools. It redirects the conversation to what actually has evidence in pediatric bone disease.

Bisphosphonates

Intravenous pamidronate, administered in cyclical infusions, has been studied in children with OI since the 1990s and remains the most widely used pharmacological agent for pediatric bone fragility, with published data showing vertebral height restoration and fracture rate reduction. Zoledronic acid is an alternative with a shorter infusion time and similar evidence base.

Oral bisphosphonates (alendronate, risedronate) have fewer pediatric data and lower bioavailability in children who cannot remain upright for 30 minutes post-dose, but are sometimes used in mild OI or glucocorticoid-induced osteoporosis.

Denosumab

Denosumab (Prolia) is a RANK-L inhibitor that reduces osteoclast activity. It has been used off-label in children with OI types III and IV where bisphosphonate response has been insufficient, and in fibrous dysplasia. A 2019 systematic review in JBMR identified denosumab as a promising option in pediatric high-turnover bone disease, though the rebound hypercalcemia on discontinuation in young children requires careful management.

Optimization of Underlying Disease and Nutrition

For most girls under 12 with low BMD that does not reach fracture-threshold severity, the first-line approach is treating the underlying condition, ensuring calcium and vitamin D adequacy, and optimizing weight-bearing physical activity. Current NIH recommendations for calcium intake in children aged 4-8 is 1,000 mg/day, rising to 1,300 mg/day for ages 9-18, and vitamin D adequacy (serum 25-OH-D at least 20 ng/mL) is foundational before any pharmacological intervention.

Clinical Takeaways for Families and Prescribers

A parent of a daughter under 12 with fragile bones will not find abaloparatide on any responsible clinician's recommendation list. The drug's developmental unknowns, its osteosarcoma black-box warning, and its contraindication in open-growth-plate patients all point in the same direction.

The Endocrine Society's 2023 clinical practice guideline on osteoporosis in premenopausal women explicitly notes that anabolic agents including teriparatide and abaloparatide have no established role in premenopausal bone disease outside of very specific secondary causes with specialist oversight, and that guideline does not address pediatric use at all because the data simply do not exist to inform a recommendation.

If your daughter has been diagnosed with low bone density or a fragility fracture condition, the appropriate pathway is referral to a pediatric endocrinologist or metabolic bone specialist, assessment for underlying causes (including celiac disease, inflammatory conditions, steroid exposure, vitamin D deficiency, and rare genetic conditions), and discussion of the bisphosphonate evidence base when pharmacological treatment is indicated.

Any clinician who suggests abaloparatide for a child under 12 should be asked directly: what peer-reviewed safety and dosing data in this age group support this recommendation? The honest answer is: none currently exist.